利用天然营养药物对抗亨廷顿病的潜力
Abhishek Kanugo1, Yogeeta Agrawal2
1Department of Pharmaceutical Quality Assurance, School of Pharmacy and Technology Management, SVKM NMIMS Global University, Dhule, Maharashtra-424001.
Current topics in medicinal chemistry
|January 16, 2026
概括
营养药,食品中的天然化合物,显示出预防和治疗亨廷顿病的前景.
科学领域:
- 神经科学是一个神经科学.
- 营养科学 营养科学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 神经退行性疾病 (NDD) 构成了全球重大健康挑战.
- 亨廷顿病 (HD) 是一种罕见的遗传性NDD,它是由亨廷丁基因 (HTT) 中的CAG三核酸重复产生的.
- 目前,没有专门的治疗方法可以治疗HD.
研究的目的:
- 审查亨廷顿病中营养药的治疗和预防潜力.
- 探索营养药物如何保护神经元损伤,氧化应激和HD中神经炎症.
- 检查营养药在改善HD的认知和行为健康方面的作用.
主要方法:
- 对亨廷顿病的营养药物现有证据的文献综述.
- 营养学机制的分析,包括抗氧化,抗炎和神经保护性质.
- 识别特定的营养保健品,对HD有潜在的益处.
主要成果:
- 营养药物通过对抗氧化应激,线粒体功能障碍,兴奋毒性和神经炎症来提供神经保护.
- 它们有助于避免缺陷的能量代谢,蛋白质错折和表观遗传改变.
- 有前途的营养保健品包括黄素,白醇,奎瑞和辅酶Q10.
结论:
- 营养药物是一种安全,易于获得和经济可行的方法来预防和治疗疾病.
- 它们的多功能特性支持神经元健康和疾病管理.
- 对特定营养保健品的进一步研究可能会导致亨廷顿病的新治疗策略.
相关概念视频
Parkinson's Disease: Treatment
987
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
987
Drug Discovery: Overview
11.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.1K
Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
560
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
560
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K


